Elevated Lp(a) and Abdominal Aortic Aneurysm: An Intriguing Association That Needs Confirmation with Well-Designed Studies

Angiology

Volumn 68, Issue 2, 2017, Pages 96-98

  Alexandrou, Aris T ^a   Tsimikas, Sotirios ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; INTERLEUKIN 6; LIPOPROTEIN A; PROTEOGLYCAN;

ABDOMINAL AORTA ANEURYSM; ACUTE CORONARY SYNDROME; ACUTE PHASE RESPONSE; AORTA ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DISULFIDE BOND; EDITORIAL; FIBRINOLYSIS; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; ABDOMINAL AORTIC ANEURYSM; HYPERLIPIDEMIA;

AORTIC ANEURYSM, ABDOMINAL; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEIN(A); RISK FACTORS;

EID: 85007307588     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319716650960     Document Type: Editorial

References (31)

1. Erbel R, Aboyans V, Boileau C, et al. ESC Committee for Practice Guidelines. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35 (41): 2873-2926.
2. Davis FM, Rateri DL, Daugherty A,. Mechanisms of aortic aneurysm formation: translating preclinical studies into clinical therapies. Heart. 2014; 100 (19): 1498-1505.
3. Mussa FF,. Screening for abdominal aortic aneurysm. J Vasc Surg. 2015; 62 (3): 774-778.
4. Li X, Zhao G, Zhang J, Duan Z, Xin S,. Prevalence and trends of the abdominal aortic aneurysms epidemic in general population - a meta-analysis. PLoS One. 2013; 8 (12): e81260.
5. Fleming C, Whitlock EP, Beil TL, Lederle FA,. Screening for abdominal aortic aneurysm: a best-evidence systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005; 142 (3): 203-211.
6. Norman PE, Jamrozik K, Lawrence-Brown MM, et al. Population based randomised controlled trial on impact of screening on mortality from abdominal aortic aneurysm. BMJ. 2004; 329 (7477): 1259.
7. Lederle FA, Johnson GR, Wilson SE, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med. 1997; 126 (6): 441-449.
8. Lederle FA, Wilson SE, Johnson GR, et al.Aneurysm Detection and Management Veterans Affairs Cooperative Study Group. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002; 346 (19): 1437-1444.
9. United Kingdom Small Aneurysm Trial Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002; 346 (19): 1445-1452.
10. Moll FL, Powell JT, Fraedrich G, et al.European Society for Vascular Surgery. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur J Vasc Endovasc Surg. 2011; 41 (suppl 1): s1-s58.
11. Tsimikas S, Willeit P, Willeit J, et al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol. 2012; 60 (21): 2218-2229.
12. Kronenberg F, Utermann G,. Lipoprotein(a): resurrected by genetics. J Intern Med. 2013; 273 (1): 6-30.
13. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG,. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013; 61 (11): 1146-1156.
14. van Dijk RA, Kolodgie F, Ravandi A, et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res. 2012; 53 (12): 2773-2790.
15. Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014; 64 (9): 851-860.
16. Scipione CA, Sayegh SE, Romagnuolo R, et al. Mechanistic insights into lipoprotein(a)-induced interleukin-8 expression: a role for oxidized phospholipid modification of apolipoprotein(a). J Lipid Res. 2015; 56 (12): 2273-2285.
17. Tsimikas S, Duff GW, Berger PB, et al. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol. 2014; 63 (17): 1724-1734.
18. Boffa MB, Koschinsky ML,. Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res. 2016; 57 (5): 745-757.
19. Norrgard O, Angquist KA, Dahlen G,. High concentrations of Lp(a) lipoprotein in serum are common among patients with abdominal aortic aneurysms. Int Angiol. 1988; 7 (1): 46-49.
20. Purushothaman KR, Purushothaman M, Levy AP, et al. Increased expression of oxidation-specific epitopes and apoptosis are associated with haptoglobin genotype: possible implications for plaque progression in human atherosclerosis. J Am Coll Cardiol. 2012; 60 (2): 112-119.
21. Kotani K, Sahebkar A, Serban MC, et al.Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Lipoprotein(a) levels in patients with abdominal aortic aneurysm: A systematic review and meta-analysis. Angiology. 2017; 68 (2): 99-108.
22. Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T,. Circulating lipoprotein(a) concentrations and abdominal aortic aneurysm presence. Interact Cardiovasc Thorac Surg. 2009; 9 (3): 467-470.
23. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003; 41 (3): 360-370.
24. Tsimikas S, Witztum JL, Miller ER, et al.Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004; 110 (11): 1406-1412.
25. Muller N, Schulte DM, Turk K, et al. IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res. 2015; 56 (5): 1034-1042.
26. Yeang C, Hung MY, Byun YS, et al. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B-100 and lipoprotein(a). J Clin Lipidology. 2016; 10 (3): 594-603.
27. Bertoia ML, Pai JK, Lee JH, et al. Oxidation-specific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol. 2013; 61 (21): 2169-2179.
28. Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2012; 60 (8): 722-729.
29. Nordestgaard BG, Chapman MJ, Ray K, et al.European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31 (23): 2844-2853.
30. Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011; 5 (5): 338-367.
31. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015; 386 (10002): 1472-1483.